Nitric oxide in-situ hydrogel for treating colitis

A nitric oxide and hydrogel technology, applied in the directions of anti-inflammatory agent, digestive system, capsule delivery, etc., can solve the problems of carrying, high efficiency, etc., and achieve easy use, good affinity and biocompatibility The effect of convenient sex, storage and transportation

Active Publication Date: 2020-11-20
WENZHOU MEDICAL UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Although the in situ gel has many advantages in rectal administration and local treatment, nitric oxide is a gas, and there is no research report on the efficient carrying of nitric oxide gas in the in situ gel
Therefore, the preparation of in situ gels that efficiently carry nitric oxide gas is the limiting bottleneck for exerting nitric oxide's therapeutic effect on colitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nitric oxide in-situ hydrogel for treating colitis
  • Nitric oxide in-situ hydrogel for treating colitis
  • Nitric oxide in-situ hydrogel for treating colitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1 Preparation of nitric oxide in situ hydrogel

[0025] According to the component ratios in Table 1, the nitric oxide in situ hydrogel of the experimental group was prepared, which specifically included the following steps:

[0026] a: Disperse polyoxyethylene-polyoxypropylene-polyoxyethylene copolymer and heparin-poloxamer in 6 times the mass of 8°C water for injection, place it in a refrigerator at 4-8°C overnight, dissolve slowly, and add 50% epidermal growth factor with equal molar mass of heparin-poloxamer, mixed to form a hydrogel matrix solution;

[0027] b: Take egg yolk phospholipids and poloxamer with a mass ratio of 1:25, mix them, dissolve them in anhydrous tert-butanol 10 times the mass at 65°C, slowly cool down until the solution solidifies, stand overnight at -10°C, and freeze-dry to obtain The loose freeze-dried powder is transferred into a stoppered bottle, filled with nitric oxide gas to saturation, added to water for injection with 5 times t...

Embodiment 2

[0033] Example 2 Application effect of nitric oxide in situ hydrogel for the treatment of colitis

[0034] (1) Establishment of colitis model animals

[0035] Male rats (6-8 weeks old) were used as research objects, and colonic perfusion with 2,4,6-trinitrobenzene sodium sulfonate was used to establish colitis model animals, and rat body weight, feces and physical activity were monitored every day . After 3 days, the animal developed diarrhea, mucus, pus and blood in the stool, and it was determined that the modeling was successful.

[0036] (2) Application effect of nitric oxide in situ hydrogel in the treatment of colitis

[0037] Rats with successful colitis modeling were selected and divided into several groups according to the design in Table 1. On days 1, 3, 5, 7, and 9, the colon was perfused with 1 mL of nitric oxide in situ hydrogel, and the rats were fed routinely. Feces were collected on day 12. On the 13th day, the animals were euthanized, and the pathophysiolog...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to nitric oxide in-situ hydrogel for treating colitis. The hydrogel comprises a hydrogel matrix and nitric oxide nanobubbles, and the nitric oxide nanobubbles are uniformly dispersed in the hydrogel matrix. The hydrogel matrix consists of a catechol-terminated polyoxyethylene-polyoxypropylene-polyoxyethylene copolymer, heparin-poloxamer and an epidermal cell growth factor, wherein the mass ratio of the catechol-terminated polyoxyethylene-polyoxypropylene-polyoxyethylene copolymer to the heparin-poloxamer is (1-5):10, and the molar mass of the epidermal growth factor is equal to the molar mass of the 50% heparin-poloxamer. The nitric oxide nanobubbles are composed of vesicles formed by wrapping nitric oxide gas with egg yolk phospholipid and poloxamer as bubble film materials, the mass ratio of the egg yolk phospholipid to the poloxamer is 1:25, the particle size range is 500-900 nm, and the concentration is 6 x 10<7> to 9 x 10<7> / mL. The nitric oxide in-situ hydrogel disclosed by the invention is perfused to a colon part and is used for treating colitis.

Description

technical field [0001] The invention relates to an in-situ preparation for treating colitis, in particular to a nitric oxide in-situ hydrogel for treating colitis. Background technique [0002] Studies have found that nitric oxide has a good therapeutic effect on inflammation. Through inflammation model animal experiments, it is found that in the early stage of inflammation, nitric oxide mainly plays an anti-inflammatory role, and its specific roles include: maintaining the integrity of microcirculation, relaxing vascular smooth muscle, increasing intestinal mucosal blood flow, and inhibiting the adhesion of platelets and leukocytes to the surface of endothelial cells and accumulation, prevent thrombosis, inhibit myeloperoxidase activity, protect the epithelial barrier and promote the repair of epithelial tissue. But in the later stage of inflammation, accompanied by the generation of superoxide anion oxygen, nitric oxide can synthesize with anion oxygen to produce peroxyni...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/06A61K9/51A61K33/00A61K47/22A61K47/36A61K47/10A61K47/24A61P1/00A61P29/00A61P1/04
CPCA61K9/06A61K9/0031A61K9/5123A61K9/5146A61K33/00A61K47/22A61K47/36A61P1/00A61P29/00A61P1/04Y02A50/30
Inventor 赵应征鲁翠涛徐荷林姚情诸葛德力童梦琪
Owner WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap